Navigation Links
Statement From Michael Hansen, CEO of Elsevier's Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005
Date:5/7/2009

PHILADELPHIA, Pennysylvania, May 7 /PRNewswire-FirstCall/ -- Elsevier, one of the world's leading publishers of scientific, technical, and medical (STM) information products and services, announced today that Michael Hansen, CEO of Elsevier's Health Sciences Division, issued the following statement in light of recent allegations of improper Australia based sponsored journal publication practices between 2000 and 2005:

"Elsevier prides itself on operating its business in the most ethical, honest and transparent manner possible. We have been stewards of the scientific record for more than 125 years and we take our role in advancing medical and scientific research seriously.

It has recently come to my attention that from 2000 to 2005, our Australia office published a series of sponsored article compilation publications, on behalf of pharmaceutical clients, that were made to look like journals and lacked the proper disclosures. This was an unacceptable practice, and we regret that it took place.

We are currently conducting an internal review but believe this was an isolated practice from a past period in time. It does not reflect the way we operate today. The individuals involved in the project have long since left the company. I have affirmed our business practices as they relate to what defines a journal and the proper use of disclosure language with our employees to ensure this does not happen again.

We will continue to partner with all scientists and clinical investigators, including those in the pharmaceutical industry, to help communicate the findings of high-quality, peer-reviewed medical research. We have strict disclosure rules in place so that readers are aware of any financial interests behind a specific article or journal, or when entire compilation products are created for pharmaceutical marketing purposes.

I understand this issue has troubled our communit
'/>"/>

SOURCE Elsevier
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
3. Anacor Files Registration Statement for Initial Public Offering
4. IsoTis Files Definitive Proxy Statement
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. Statement on Direct-To-Consumer Genetic Testing
7. Coherent Announces Restatement Related to Stock-Based Compensation
8. XTL Biopharmaceuticals: AGM/EGM Statements
9. Statement from GPhA President and CEO Kathleen Jaeger on FDAs Generic Initiative
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. CCPM Issues Statement on FDAs GIVE Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... 2014 The report provides basic ... classification, application and industry overview. This report also ... structure. Production is separated by regions, technology and ... equipment, downstream client survey, marketing channels, industry development ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... (Santa Barbara, Calif.) A team of physicists at UC ... many different colors. By aiming high- and low-frequency laser beams ... from their cores, accelerated, and then smashed back into the ... light simultaneously. Their findings appear in the current issue of ...
... 2012  Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology ... of patented technologies in the field of transplantation ... its subsidiary DiaKine Therapeutics Inc. received European patent ... be used to treat diabetes, atherosclerosis and other ...
... RIDGE, N.J., March 28, 2012  Regado Biosciences, Inc., a ... with active control agents, announced that David J. Mazzo, ... & Company,s 11th Annual Healthcare Conference at 10 a.m. ... Palace Hotel in New York City. The ...
Cached Biology Technology:UCSB Physicists mix 2 lasers to create light at many frequencies 2UCSB Physicists mix 2 lasers to create light at many frequencies 3Islet Sciences Announces DiaKine Therapeutics' Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection 2Islet Sciences Announces DiaKine Therapeutics' Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection 3Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 2Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 3
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... offering. One major trend emerging in ... Multimodal biometric systems utilize more than one characteristic of ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... process of aging disturbs a broad range of cellular mechanisms ... models using fuzzy logic might help to unravel these complexities ... to a study from Drexel University in Philadelphia and Children,s ... in aging is to develop integrated models of a unifying ...
... in newborn mice take around two weeks to become fully ... to understanding of the cold sensing protein TRPM8 (pronounced trip-em-ate), ... by David McKemy of the University of Southern California. ... cold sensing circuit starts to develop in utero but does ...
... shown fathers who are active in their children,s upbringing can ... being. Now, a new study by University of South ... is born may play an important role in preventing death ... infant is black. The USF team sought to ...
Cached Biology News:Fuzzy logic predicts cell aging 2When do newborns first feel cold? 2Father involvement in pregnancy could reduce infant mortality 2
From formula-fed bovine calves Sterile, Cell culture tested...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... may be carried out using this high ... System control and data processing is provided ... The elegant, powerful and very easy to use ... and 2000., The supplied automatic sample injector has ...
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
Biology Products: